European approval of paediatric license extension of secukinumab (Cosentyx) for moderate-to-severe plaque psoriasis

Approval based on two phase 3 studies in children and adolescents aged six to <18 years. In both studies, low-dose (75–150 mg) and high-dose (75–300 mg) secukinumab was effective in rapidly improving skin symptoms and quality of life.

PharmaTimes